AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tzika, A. A.
Right arrow Articles by Kirks, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tzika, A. A.
Right arrow Articles by Kirks, D. R.

American Journal of Neuroradiology, Vol 14, Issue 6 1267-1281, Copyright © 1993 by American Society of Neuroradiology


ARTICLES

Clinical proton MR spectroscopy of neurodegenerative disease in childhood

AA Tzika, WS Ball Jr, DB Vigneron, RS Dunn and DR Kirks
Department of Radiology, Children's Hospital Medical Center, Cincinnati, OH 45229.

PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine- , and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.


This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
M. A. A. P. Willemsen, M. van der Graaf, M. S. van der Knaap, A. Heerschap, P. H. M. F. van Domburg, F. J. M. Gabreels, and J. J. Rotteveel
MR Imaging and Proton MR Spectroscopic Studies in Sjogren-Larsson Syndrome: Characterization of the Leukoencephalopathy
AJNR Am. J. Neuroradiol., April 1, 2004; 25(4): 649 - 657.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
W. S. Ball Jr
PEDIATRIC NEURORADIOLOGY
AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 29 - 36.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
G Tedeschi, S Bonavita, N W Barton, A Bertolino, J A Frank, N J Patronas, J R Alger, and R Schiffmann
Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease
J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 72 - 79.
[Abstract] [Full Text]


Home page
J Child NeurolHome page
T. Hashimoto, M. Tayama, M. Miyazaki, Y. Yoneda, T. Yoshimoto, M. Harada, H. Miyoshi, M. Tanouchi, and Y. Kuroda
Differences in Brain Metabolites Between Patients With Autism and Mental Retardation as Detected by in Vivo Localized Proton Magnetic Resonance Spectroscopy
J Child Neurol, February 1, 1997; 12(2): 91 - 96.
[Abstract] [PDF]